ADHERENCE, COMPLIANCE AND SAFETY WITH SUBCUTANEOUS HIGH-DOSE HYPOALLERGENIC HOUSE DUST MITES PREPARATIONS DURING TWO YEARS TREATMENT

T. Carrillo Díaz 1, J.A.Cumplido Bonny1, Hernández-Peña J2, Rodríguez-Marco A2
1 Allergy Unit. Hospital Dr. Negrín, Las Palmas de Gran Canaria. 2 Medical Department. Merck SL. Spain

BACKGROUND

In order to achieve the greatest possible efficiency, both in the long and short term, the patients’ proper adhesion to the treatment is mandatory. Our objective was to determine the level of adherence, compliance by patients and safety during the first two years of treatment with these high-dose modified preparations in daily practice.

METHODS

A retrospective observational multicenter study with the participation of 42 researchers was carried out. From May to December 2013; 460 patients with house dust mites IgE mediated allergic rhinoconjunctivitis and/or bronchial asthma, were included. Once administered the first dose, adherent was the patient who did not suspend the treatment on its own initiative. Therapeutic compliance was defined by the administration of at least 80% of the doses provided during the evaluation period.

RESULTS

High adherence and compliance where observed with these subcutaneous high-dose hypoallergenic house dust mites preparations after two years of treatment (83, 7% and 85, 3% respectively).

- SCIT with these high-dose modified house dust mites extract showed a high safety profile.

CONCLUSIONS

High adherence and compliance where observed with these subcutaneous high-dose hypoallergenic house dust mites preparations after two years of treatment (83, 7% and 85, 3% respectively).

- SCIT with these high-dose modified house dust mites extract showed a high safety profile.

DISCLOSURES

TCD and JACB: in relation to this presentation declare a research grant from Merck Spain. JHP and ARM are employees of Merck-Serono Spain.

Poster presented at June 2014